Methotrexate and Malignancy in Rheumatoid Arthritis: Evidence, Risks, and Clinical Considerations

Clicks: 3
ID: 326997
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #37 of 40 articles by views in modern rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In this review, we summarized the current evidence on the risks of incident malignancy and cancer recurrence in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX). Before considering the effect of MTX, it is important to recognize the malignancy risk associated with RA itself. The overall risk of malignancy in patients with RA modestly increased, as per two meta-analyses, although Japanese studies report inconsistent findings, with one showing a slightly decrease and another a slight increase. The risk of malignant lymphoma has increased, whereas the risk of colorectal cancer appears reduced. Additionally, there are concerns regarding the increased risk of lung and skin cancers. However, there is limited evidence specific to patients with RA treated with MTX. According to an Australian report, patients have a higher risk of overall malignancy, with an increased risk of malignant lymphoma, lung cancer, and melanoma. Studies comparing MTX with tumor necrosis factor inhibitors have reported no significant difference in the overall malignancy risk or increased malignancy risk. In White patients, MTX has been associated with an increased risk of recurrence in patients with RA and a history of non-melanoma skin cancer. There is insufficient evidence regarding the risks of MTX use in patients with RA and malignancy. Therefore, decisions regarding MTX use should be made individually based on shared decision-making, and careful follow-up is necessary.
Reference Key
openalex_W7204876964 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors S. Iwata, Masahiro Tada, Ryuji Koike, Yuji Yamanishi, Mie Fusama, Haruka Tsuchiya, Kunihiro Yamaoka, Hideto Kameda
Journal modern rheumatology
Year 2026
DOI
10.1093/mr/roag080
URL
https://doi.org/10.1093/mr/roag080
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.